Uniqure NV at Barclays Global Healthcare Conference Transcript
Good afternoon. My name is Gena Wang. I'm a SMID cap biotech analyst. It's my great pleasure to introduce our first speaker, Sander Van Deventer, Chief Scientific Officer of uniQure.
Thank you very much, Gena. It's a pleasure to be here at the conference. Thank you very much for the invitation. It's also a pleasure to introduce our company to you. I will be making some forward-looking statements, as you see here, during my presentation.
So uniQure is a gene therapy company, and the mission of uniQure is to deliver curative one-time therapies to transform the lives of patients, basically long-acting therapies. So the drivers behind our strategy, our pipelines, we have developed a pipeline of gene therapy candidates, which are focused on the liver and on the CNS. We'll discuss that in a little more detail. If you want to make a product, you need to have manufacturing. That's true for any drug,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |